Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

References

• LimSSVosTFlaxmanADA comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201338098592224226023245609
   PubMed Web of Science ®Google Scholar
• RogerVLGoASLloyd-JonesDMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2012 update: a report from the American Heart AssociationCirculation20121251e2e22022179539
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Vital signs: awareness and treatment of uncontrolled hypertension among adults –United States, 2003–2010MMWR Morb Mortal Wkly Rep20126170370922951452
   PubMedGoogle Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• ClarkCETaylorRSShoreACUkoumunneOCCampbellJLAssociation of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysisLancet2012379981990591422293369
   PubMed Web of Science ®Google Scholar
• IsekiKKimuraYWakugamiKComparison of the effect of blood pressure on the development of stroke, acute myocardial infarction, and end-stage renal diseaseHypertens Res200023214314910770261
   PubMed Web of Science ®Google Scholar
• GuQDillonCFBurtVLGillumRFAssociation of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertensionAm J Hypertens2010231384519851295
   PubMed Web of Science ®Google Scholar
• AllisonSJHypertension: high systolic blood pressure is a major contributor to ESRD riskNat Rev Nephrol201283132
   Google Scholar
• HsuCYMcCullochCEDarbinianJGoASIribarrenCElevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney diseaseArch Intern Med2005165892392815851645
   PubMedGoogle Scholar
• KannelWBRisk stratification in hypertension: new insights from the Framingham StudyAm J Hypertens2000131 Pt 23S10S10678282
   PubMed Web of Science ®Google Scholar
• BellEKGaoLJuddSBlood pressure indexes and end-stage renal disease risk in adults with chronic kidney diseaseAm J Hypertens201225778979622573012
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRShanifarSRENAAL Study GroupEffects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyArch Intern Med2003163131555156512860578
   PubMed Web of Science ®Google Scholar
• OgdenLGHeJLydickEWheltonPKLong-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratificationHypertension200035253954310679494
   PubMed Web of Science ®Google Scholar
• SarafidisPAGeorgianosPBakrisGLResistant hypertension – its identification and epidemiologyNat Rev Nephrol201291515823165303
   PubMed Web of Science ®Google Scholar
• PersellSDPrevalence of resistant hypertension in the United States, 2003–2008Hypertension20115761076108021502568
   PubMed Web of Science ®Google Scholar
• ErdineSHow do compliance, convenience, and tolerability affect blood pressure goal rates?Am J Cardiovasc Drugss201212529530222920049
   PubMed Web of Science ®Google Scholar
• MarshallIJWolfeCDMcKevittCLay perspectives on hypertension and drug adherence: systematic review of qualitative researchBMJ2012345e395322777025
   PubMed Web of Science ®Google Scholar
• RoarkRFShahBRUdayakumarKPetersonEDThe need for transformative innovation in hypertension managementAm Heart J2011162340541121884855
   PubMed Web of Science ®Google Scholar
• KrakoffLRSystems for care of hypertension in the United StatesJ Clin Hypertens (Greenwich)20068642042616760681
   PubMedGoogle Scholar
• JollesEPClarkAMBraamBGetting the message across: opportunities and obstacles in effective communication in hypertension careJ Hypertens20123081500151022635137
   PubMed Web of Science ®Google Scholar
• OkonofuaECSimpsonKNJesriARehmanSUDurkalskiVLEganBMTherapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goalsHypertension200647334535116432045
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRNational Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pessure, National High Blood Pressure Education Program Coordinating CommitteeThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• GradmanAHRationale for triple-combination therapy for management of high blood pressureJ Clin Hypertens (Greenwich)2010121186987821054774
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogISCOPE Study GroupThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• PepineCJHandbergEMCooper-DeHoffRMINVEST InvestigatorsA calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialJAMA2003290212805281614657064
   PubMed Web of Science ®Google Scholar
• WrightJTJrDunnJKCutlerJAALLHAT Collaborative Research GroupOutcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJAMA2005293131595160815811979
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• BlackHRTriple fixed-dose combination therapy: back to the pastHypertension2009541192219470871
   PubMed Web of Science ®Google Scholar
• HobbsLFA broad ranged antihypertensive combination (Ser-Ap-Es)Va Med Mon (1918)196390283013954875
   PubMedGoogle Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ20033267404142712829555
   PubMed Web of Science ®Google Scholar
• van ZwietenPAFarsangCCombination of antihypertensive drugs from a historical perspectiveBlood Press2005142727916036483
   PubMed Web of Science ®Google Scholar
• PanjabiSLaceyMBancroftTCaoFTreatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patientsJ Am Soc Hypertens201371466023321404
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• FeldmanRDZouGYVandervoortMKWongCJNelsonSAFeaganBGA simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trialHypertension200953464665319237683
   PubMed Web of Science ®Google Scholar
• MasonRPMarchePHintzeTHNovel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipineArterioscler Thromb Vasc Biol200323122155216314512371
   PubMed Web of Science ®Google Scholar
• Preston MasonRPleiotropic effects of calcium channel blockersCurr Hypertens Rep201214429330322610475
   PubMed Web of Science ®Google Scholar
• PhillipsJEPreston MasonRInhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactionsAtherosclerosis2003168223924412801606
   PubMed Web of Science ®Google Scholar
• WitztumJLThe oxidation hypothesis of atherosclerosisLancet199434489257937957916078
   PubMed Web of Science ®Google Scholar
• SteinbergDLow density lipoprotein oxidation and its pathobiological significanceJ Biol Chem19972723420963209669261091
   PubMed Web of Science ®Google Scholar
• MasonRPMechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidenceAtherosclerosis2002165219119912417269
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPCAMELOT InvestigatorsEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
   PubMed Web of Science ®Google Scholar
• TomaLStancuCSSandaGMSimaAVAnti-oxidant and anti-inflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversibly glycated LDLBiochem Biophysi Res Commun20114111202207
   PubMed Web of Science ®Google Scholar
• Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative studyJAMA19772373255261576159
   PubMed Web of Science ®Google Scholar
• TziomalosKAthyrosVGMikhailidisDPKaragiannisAHydrochlorothiazide vs chlorthalidone as the optimal diuretic for the management of hypertensionCurr Pharm Des Epub12262012
   Web of Science ®Google Scholar
• LundBCErnstMEThe comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veteransJ Clin Hypertens (Greenwich)201214962362922947361
   PubMed Web of Science ®Google Scholar
• RoushGCHolfordTRGuddatiAKChlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analysesHypertension20125961110111722526259
   PubMed Web of Science ®Google Scholar
• DiNicolantonioJJHydrochlorothiazide: is it a wise choice?Expert Opin Pharmacother201213680781422424420
   PubMed Web of Science ®Google Scholar
• JadhavMYeolaCZopeGNabarAAliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its developmentJ Postgrad Med2012581323822387646
   PubMed Web of Science ®Google Scholar
• WoodJMMaibaumJRahuelJStructure-based design of aliskiren, a novel orally effective renin inhibitorBiochem Biophys Res Commun2003308469870512927775
   PubMed Web of Science ®Google Scholar
• AngeliFReboldiGMazzottaGSafety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditionsCurr Drug Saf201271768522663961
   PubMedGoogle Scholar
• PowersBJCoeytauxRRDolorRJUpdated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new informationJ Gen Intern Med201227671672922147122
   PubMed Web of Science ®Google Scholar
• ChenYMengLShaoHYuFAliskiren vs other antihypertensive drugs in the treatment of hypertension: a meta-analysisHypertens Res201336325226123154589
   PubMed Web of Science ®Google Scholar
• MusiniVMFortinPMBassettKWrightJMBlood pressure lowering efficacy of renin inhibitors for primary hypertensionCochrane Database Syst Rev20084CD00706618843743
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFMazzottaGAliskiren versus ramipril in hypertensionTher Adv Cardiovasc Dis20104319320020418269
   PubMedGoogle Scholar
• GaoDNingNNiuXWeiJSunPHaoGAliskiren vs angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trialsAm J Hypertens201124561362121293386
   PubMed Web of Science ®Google Scholar
• GaddamKKOparilSRenin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?Curr Opin Nephrol Hypertens200817548449018695389
   PubMed Web of Science ®Google Scholar
• GercVBuksaMLozaVKulicMIs aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?Med Arh200963634334920380117
   PubMedGoogle Scholar
• HollenbergNKFisherNDPriceDAPathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin systemHypertension19983233873929740600
   PubMed Web of Science ®Google Scholar
• WolnyAClozelJPReinJFunctional and biochemical analysis of angiotensin II-forming pathways in the human heartCirc Res19978022192279012744
   PubMed Web of Science ®Google Scholar
• BombackASKlemmerPJThe incidence and implications of aldosterone breakthroughNat Clin Pract Nephrol20073948649217717561
   PubMedGoogle Scholar
• ONTARGET InvestigatorsYusufSTeoKKPoqueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJALTITUDE InvestigatorsCardiorenal end points in a trial of aliskiren for type 2 diabetesN Engl J Med2012367232204221323121378
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDHHypertension management: rationale for triple therapy based on mechanisms of actionCardiovasc Ther Epub1122012
   Web of Science ®Google Scholar
• PhilippTSmithTRGlazerRTwo multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertensionClin Ther200729456358017617280
   PubMed Web of Science ®Google Scholar
• PoolJLGlazerRWeinbergerMAlvaradoRHuangJGraffAComparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsClin Ther2007291617317379047
   PubMed Web of Science ®Google Scholar
• JuddEJaimesEAAliskiren, amlodipine and hydrochlorothiazide triple combination for hypertensionExpert Rev Cardiovasc Ther201210329330322390800
   PubMedGoogle Scholar
• MurrayAVKoenigWGarcia-PuigJPatelSUddinAZhangJSafety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label studyJ Clin Hypertens (Greenwich)2012141282182723205748
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEffect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover studyExpert Opin Pharmacother20111291351135821510830
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909
   PubMed Web of Science ®Google Scholar
• BrownMJMcInnesGTPapstCCZhangJMacDonaldTMAliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trialLancet2011377976231232021236483
   PubMed Web of Science ®Google Scholar
• ChrysantSGMurrayAVHoppeUCLong-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertensionCurr Med Res Opin201026122841284921062137
   PubMed Web of Science ®Google Scholar
• StergiouGSMakrisTPapavasiliouMEfstathiouSManolisAComparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapyJ Hypertens200523488388915775795
   PubMed Web of Science ®Google Scholar
• VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig20092911125
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEEuropean Society of HypertensionReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens200927112121215819838131
   PubMed Web of Science ®Google Scholar
• LacourcièreYTaddeiSKonisGFangHSeverinTZhangJClinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trialJ Hypertens201230102047205522828090
   PubMed Web of Science ®Google Scholar
• FerdinandKCWeitzmanRIsraelMLeeJPurkayasthaDJaimesEAEfficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertensionJ Am Soc Hypertens20115210211321414565
   PubMed Web of Science ®Google Scholar
• FerdinandKCWeitzmanRPurkayasthaDSridharanKJaimesEAAliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertensionJ Am Soc Hypertens20126321922722305998
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens200725121722617143194
   PubMed Web of Science ®Google Scholar
• LijnenPFagardRStaessenJAmeryAEffect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertensionBr J Clin Pharmacol19811233873927028060
   PubMed Web of Science ®Google Scholar
• O’BrienEBartonJNussbergerJAliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blockerHypertension200749227628417159081
   PubMed Web of Science ®Google Scholar
• DugganSTChwiedukCMCurranMPAliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertensionDrugs201070152011204920883056
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet2007370958322122917658393
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin Angiotensin Aldosterone Syst20078419019818205098
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation2009119341742519139391
   PubMed Web of Science ®Google Scholar
• KushiroTItakuraHAboYGotouHTeraoSKeefeDLLong-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertensionHypertens Res200932316917519262478
   PubMed Web of Science ®Google Scholar
• DuprezDAMungerMABothaJKeefeDLCharneyANAliskiren for geriatric lowering of systolic hypertension: a randomized controlled trialJ Hum Hypertens201024960060820033075
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdTrenkwalderPHollandersGZhaoYLiaoWLong-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertensionCurr Med Res Opin200925495195919257800
   PubMed Web of Science ®Google Scholar
• TohSReichmanMEHoustounMComparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone systemArch Intern Med2012172201582158923147456
   PubMedGoogle Scholar
• de la SierraAMitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin systemJ Hum Hypertens200923850351119148104
   PubMed Web of Science ®Google Scholar